Cargando…

Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes

Metabolism alters markedly with advancing gestation, characterized by progressive insulin resistance, dyslipidemia, and raised serum bile acids. The nuclear receptor farnesoid X receptor (FXR) has an integral role in bile acid homeostasis and modulates glucose and lipid metabolism. FXR is known to b...

Descripción completa

Detalles Bibliográficos
Autores principales:	McIlvride, Saraid, Nikolova, Vanya, Fan, Hei Man, McDonald, Julie A. K., Wahlström, Annika, Bellafante, Elena, Jansen, Eugene, Adorini, Luciano, Shapiro, David, Jones, Peter, Marchesi, Julian R., Marschall, Hanns-Ulrich, Williamson, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Physiological Society 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732461/ https://www.ncbi.nlm.nih.gov/pubmed/31237448 http://dx.doi.org/10.1152/ajpendo.00407.2018

Ejemplares similares

Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia
por: Pataia, Vanessa, et al.
Publicado: (2020)

Maternal glucose homeostasis is impaired in mouse models of gestational cholestasis
por: Bellafante, Elena, et al.
Publicado: (2020)

Bile acids and their respective conjugates elicit different responses in neonatal cardiomyocytes: role of Gi protein, muscarinic receptors and TGR5
por: Ibrahim, Effendi, et al.
Publicado: (2018)

A progesterone-brown fat axis is involved in regulating fetal growth
por: McIlvride, Saraid, et al.
Publicado: (2017)

Ursodeoxycholic acid improves feto-placental and offspring metabolic outcomes in hypercholanemic pregnancy
por: Borges Manna, Luiza, et al.
Publicado: (2020)

Sulfated Progesterone Metabolites That Enhance Insulin Secretion via TRPM3 Are Reduced in Serum From Women With Gestational Diabetes Mellitus
por: Fan, Hei Man, et al.
Publicado: (2022)

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2018)

Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model
por: Anfuso, Beatrice, et al.
Publicado: (2020)

Changes in LXR signaling influence early-pregnancy lipogenesis and protect against dysregulated fetoplacental lipid homeostasis
por: Nikolova, Vanya, et al.
Publicado: (2017)

Enhanced Microbial Bile Acid Deconjugation and Impaired Ileal Uptake in Pregnancy Repress Intestinal Regulation of Bile Acid Synthesis
por: Ovadia, Caroline, et al.
Publicado: (2019)

Gestational disruptions in metabolic rhythmicity of the liver, muscle, and placenta affect fetal size
por: Papacleovoulou, Georgia, et al.
Publicado: (2017)

Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis
por: Roda, A, et al.
Publicado: (2017)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

Obeticholic acid reduces biliary and hepatic matrix metalloproteinases activity in rat hepatic ischemia/reperfusion injury
por: Ferrigno, Andrea, et al.
Publicado: (2020)

Obeticholic Acid Reduces Kidney Matrix Metalloproteinase Activation Following Partial Hepatic Ischemia/Reperfusion Injury in Rats
por: Palladini, Giuseppina, et al.
Publicado: (2022)

The Importance of Gestation-Adjusted Birthweight Centile in Assessment of Fetal Growth in Metabolic Conditions
por: Ovadia, Caroline, et al.
Publicado: (2018)

Obeticholic Acid Protects against Gestational Cholestasis-Induced Fetal Intrauterine Growth Restriction in Mice
por: Chen, Wei, et al.
Publicado: (2019)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury
por: Ferrigno, Andrea, et al.
Publicado: (2018)

Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
por: Edwards, JE, et al.
Publicado: (2016)

Cyp3a11 is not essential for the formation of murine bile acids
por: Wahlström, Annika, et al.
Publicado: (2017)

Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy
por: Ovadia, Caroline, et al.
Publicado: (2020)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
por: Feng, Cynthia
Publicado: (2018)

Development of a New Patient-reported Outcome Instrument to Evaluate Treatments for Scars: The SCAR-Q
por: Klassen, Anne F., et al.
Publicado: (2018)

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
por: Roth, Jonathan D., et al.
Publicado: (2019)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022)

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice
por: Liu, Szu-Yu, et al.
Publicado: (2022)

Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis
por: Al-Dury, Samer, et al.
Publicado: (2018)

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2020)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2019)

Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
por: Roberts, Surain B., et al.
Publicado: (2020)

Real-world experience with obeticholic acid in patients with primary biliary cholangitis
por: D’Amato, Daphne, et al.
Publicado: (2021)

Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites
por: Yan, Kathleen, et al.
Publicado: (2021)

Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat
por: Zhang, Hanlin, et al.
Publicado: (2021)

Paternal cholestasis exacerbates obesity-associated hypertension in male offspring but is prevented by paternal ursodeoxycholic acid treatment
por: Pataia, Vanessa, et al.
Publicado: (2018)

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_94qf5vrhqgs14m1ebfg1h1ea04